From: Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
ALL ( n = 218) | High-dose group ( n = 117) | Low-dose group ( n = 101) | P value | |
---|---|---|---|---|
ECMO device | < 0.001 | |||
CardioHelp | 31 (26.5) | 99 (98) | ||
RotaFlow | 86 (73.5) | 2 (2) | ||
Canula site out | ||||
Jugular vein | 3 (1.4) | 3 (2.6) | 0 | |
Femoral vein | 215 (98.6) | 114 (97.4) | 101 (100) | |
Canula site in | ||||
Jugular vein | 135 (61.9) | 113 (96.6) | 22 (21.8) | |
Subclavian vein | 2 (0.9) | 2 (1.7) | 0 | |
Femoral vein | 81 (37.2) | 2 (1.7) | 79 (78.2) | |
Canula size out | 23 (23–35) | 23 (23–23) | 25 (25–25) | < 0.001 |
Canula size in | 17 (17–23) | 17 (17–17) | 23 (21–25) | < 0.001 |
ECMO runtime, median (IQR), days | 9 (5–14) | 8 (5–12) | 11 (7–17) | 0.003 |
ECMO flow, median (IQR), liter per minute | 3.8 (3.3–4.4) | 3.5 (2.8–3.9) | 4.4 (3.8–4.9) | < 0.001 |
Days from mechanical ventilation to ECMO implantation, median (ICR) | 1 (0–3) | 1 (0–3) | 1 (0–4) | 0.185 |
Antiplatelet therapy pre-ECMO | ||||
Aspirin | 31 (14) | 13 (11) | 18 (18) | 0.157 |
P2Y12-inhibitors | 6 (3) | 2 (2) | 4 (4) | 0.311 |
Antiplatelet therapy during ECMO, n (%) | ||||
Aspirin | 27 (12) | 9 (8) | 18 (18) | 0.024 |
P2Y12-inhibitors | 5 (2) | 0 | 5 (5) | 0.015 |
Baseline fibrinogen, g/L (IQR) | 4.7 (3.3–6.2) | 6.7 (3.3–6.4) | 4.8 (3.4–6.1) | 0.611 |
Minimal fibrinogen, g/L (IQR) | 2.2 (1.4–3.4) | 2.5 (1.6–3.5) | 2.0 (1.2–3.4) | 0.030 |
Baseline d-dimers, mg/L (IQR) | 7.6 (3.6–15.4) | 5.4 (2.6–12.7) | 8.3 (4.4–16.5) | 0.010 |
Maximum d-dimers, mg/L (IQR) | 30 (19.3–35) | 28.5 (13–30) | 35 (33.4–35) | < 0.001 |
Baseline antithrombin III, % (IQR) | 67 (53–86) | 79 (60–93) | 60 (44–75) | < 0.001 |
Minimum antithrombin III, % (IQR) | 59 (45–76) | 69 (56–84) | 48 (37–62) | < 0.001 |
Antithrombin III substitution, n (%) | 29 (13.3) | 8 (6.8) | 21 (21) | 0.002 |
Baseline thrombocyte count, thousand / µL (IQR) | 174 (101–265) | 167 (109–269) | 183 (97–263) | 0.878 |
Minimum thrombocyte count, thousand / µL (IQR) | 62 (36–88) | 65 (33–106) | 60 (40–81) | 0.868 |
Received PCC, n (%) | 36 (16.5) | 8 (6.8) | 26 (25.7) | < 0.001 |
Received tranexamic acid, n (%) | 113 (51.8) | 61 (52.1) | 52 (51.5) | 0.924 |